Intellect Neurosciences, Inc. is a development-stage biopharmaceutical company engaged in the discovery and development of therapeutic products designed to slow, arrest and ultimately prevent Alzheimer's disease and other serious aging disorders.
"10 million baby boomers will develop Alzheimer's disease"
(As stated in 2008 Alzheimer's Disease Facts and Figures published by the Alzheimer's Association)
|
| Legal Notice |
|
Tuesday, March 03, 2009
Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
...read more
Wednesday, January 07, 2009
Intellect Neurosciences, Inc. Grants Top Tier Global Pharmaceutical Company License to Certain Alzheimer's Patents and Patent Applications
...read more
Friday, November 21, 2008
Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
...read more
|
|
